HC Wainwright Issues Pessimistic Forecast for MLTX Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Investment analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.77) per share for the quarter, down from their previous forecast of ($0.69). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.72) EPS and FY2025 earnings at ($3.00) EPS.

Several other brokerages also recently issued reports on MLTX. The Goldman Sachs Group cut their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Needham & Company LLC increased their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, Wedbush reiterated an “outperform” rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $83.20.

MoonLake Immunotherapeutics Trading Down 4.9 %

MLTX stock opened at $39.71 on Monday. The firm has a 50-day moving average of $46.49 and a two-hundred day moving average of $48.95. The firm has a market capitalization of $2.54 billion, a PE ratio of -30.78 and a beta of 1.28. MoonLake Immunotherapeutics has a one year low of $37.55 and a one year high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.09).

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MLTX. PNC Financial Services Group Inc. boosted its stake in MoonLake Immunotherapeutics by 3.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company’s stock valued at $460,000 after purchasing an additional 320 shares during the period. Deutsche Bank AG boosted its holdings in MoonLake Immunotherapeutics by 59.8% during the fourth quarter. Deutsche Bank AG now owns 903 shares of the company’s stock valued at $49,000 after purchasing an additional 338 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of MoonLake Immunotherapeutics by 1.9% in the 3rd quarter. GSA Capital Partners LLP now owns 22,127 shares of the company’s stock valued at $1,116,000 after purchasing an additional 403 shares during the period. Geode Capital Management LLC raised its holdings in shares of MoonLake Immunotherapeutics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 58,950 shares of the company’s stock worth $3,192,000 after buying an additional 540 shares in the last quarter. Finally, DnB Asset Management AS raised its stake in MoonLake Immunotherapeutics by 11.3% during the fourth quarter. DnB Asset Management AS now owns 8,356 shares of the company’s stock worth $452,000 after acquiring an additional 847 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.